A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2019
At a glance
- Drugs CPI 613 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 28 May 2019 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
- 14 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 May 2019.
- 14 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 May 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History